tbuckley/cabot-search huggingface dataset:
Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.
Authors: Eline Menu, Josefina Garcia, Xiangao Huang, Maurizio Di Liberto, Peter Toogood, Isan Chen, Karin Vanderkerken, Selina Chen-Kiang
Journal: Blood (2007)
From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa
Authors: Noah Haber, Frank Tanser, Jacob Bor, Kevindra Naidu, Tinofa Mutevedzi, Kobus Herbst, Kholoud Porter, Deenan Pillay, Till Bärnighausen
Journal: The Lancet HIV (2017)
Frequency and Prognostic Impact of CD8 Expression In 5,523 Patients with Chronic Lymphocytic Leukemia (CLL) In Relation to Chromosomal Aberrations, IGHV Mutational Status and ZAP-70 Expression.
Authors: Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
Journal: Blood (2010)
Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST).
Authors: E Van Cutsem, Marc Peeters, H Gerlderblom, J Vermorken, F Viret, B Glimelius, F Ciardiello, E Gallerini, D Weber, Y Humblet
Journal: Annals of Oncology (2007)
New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).
Authors: Daniel A. Pollyea, Andrew S. Artz, Wendy Stock, Christopher Daugherty, Lucy Godley, Olatoyosi M. Odenike, Elizabeth Rich, Sonali M. Smith, Todd Zimmerman, Yanming Zhang, Dezheng Huo, Richard Larson, Koen Van Besien
Journal: Blood (2006)
Combined Low-Dose Homoharringtonine, Cytarabine and Granulocyte Colony-Stimulating Factor for Patients with Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Transformed From MDS
Authors: Lingyun Wu, Xiao Li, Chunkang Chang, Jiying Shu, Li Xu, Zheng Zhang
Journal: Blood (2010)
Comparison of Clinical Outcomes and Day 30 Lymphocyte Recovery Between Two aGVHD Prophylaxis Regimens In Matched Unrelated Hematopoietic Stem Cell Transplant (MUD) Patients
Authors: Zartash Gul, Mustafa Abdul-Hussein, Ivo Ditah, Joseph P. Uberti, Muneer H. Abidi, Lois Ayash, Lawrence G. Lum, Voravit Ratanatharathorn, Zaid Al-Kadhimi
Journal: Blood (2010)
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study.
Authors: Paul G. Richardson, Asher A. Chanan-Khan, Sagar Lonial, Amrita Y. Krishnan, Michael P. Carroll, Maher Albitar, Justin Kopit, David Berman, Kenneth C. Anderson
Journal: Blood (2009)
Cost-Effectiveness Analysis (CEA) of Conventional Stem Cell Transplantation (CST) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with AML and MDS.
Authors: Osamu Imataki, Takeshi Kamioka, Takashi Fukuda, Ryuji Tanosaki, Yoichi Takaue
Journal: Blood (2007)
A Framework for Disseminating Clinical Best Practices in the VA Health System
Authors: Shereef M. Elnahal, Carolyn M. Clancy, David J. Shulkin
Journal: JAMA (2017)

In this Viewpoint, the Under Secretary for Health of the Veterans Health Administration and colleagues describe the agency's Diffusion of Excellence program, a learning health system approach to aligning best practices and agency system assets for rapid dissemination of clinical best practices.
Age and Disease Status Are Important Risk Factors for Outcome after Reduced Intensity Conditioning (RIC) Umbilical Cord Blood Transplantation (UCBT) in Adults
Authors: Sabine Fürst, Catherine Faucher, Jean El Cheikh, Jean Marie Boher, Patrick Ladaique, Claude Lemarie, Norbert Vey, Reda Bouabdallah, Anne Marie Stoppa, Hugues de Lavallade, Mohamad Mohty, Christian Chabannon, Didier Blaise
Journal: Blood (2008)
Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Ritiximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.
Authors: Lisa M. Rimsza, Michael L. LeBlanc, Robin A. Roberts, Joseph M. Unger, Thomas P. Miller, Constantine M. Sabalos, Ralph R. Martel, Elias Campo, Andreas Rosenwald, Joseph M. Connors, Laurie H. Sehn, Natalie Johnson, Randy D. Gascoyne
Journal: Blood (2007)
Bendamustine HCl (TREANDATM) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).
Authors: Katherine Sue Robinson, Michael E. Williams, Philip Cohen, Anil Tulpule, Richard H. van der Jagt, Jordan A. Herst, Robin M. Joyce, Alberto Bessudo, Bernard Lemieux, Lee S. Schwartzberg, Jennifer Oliver, Ely Benaim
Journal: Blood (2005)
Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.
Authors: Andrew C. Grigg, Peter Shuttleworth, John Reynolds, Jeff Szer, Anthony P. Schwarer, Andrew W. Roberts, Ken F. Bradstock, Chi-Hung Hui, Richard Herrmann, Peter Ebeling
Journal: Blood (2004)
Asthma—Here Today, Gone Tomorrow?
Authors: Helen M. Hollingsworth, George T. O’Connor
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CD26 Blockade by Humanized Monoclonal Antibody Leads to Prophylaxis and Treatment of Graft-Versus-Host Disease (GVHD) in Hu-PBL-NOG Model Mice,
Authors: Ryo Hatano, Kei Ohnuma, Taketo Yamada, Takaaki Ooki, Junpei Yamamoto, Kaoru Komoriya, Yukiko Iwata, Nam H. Dang, Chikao Morimoto
Journal: Blood (2011)
mTORC1 and mTORC2 regulate cell proliferation in Glioblastoma multiforme
Authors: Brian Forzani, Nicholas Gulati, Mike Kharazian, Amrith Jamoona, Alex Braun, Kaushik Das, Raj Murali, Meena Jhanwar-Uniyal
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

2354 

Human malignant glioblastoma multiforme (GBM) develops as the resultof stepwise accumulations of multiple genetic alterations. The PI3K/PTEN-AKT/mTOR signaling pathway plays a critical role in oncogenesis due to the loss of tumor suppressor PTEN. The downstream signaling kinase, mammalian target of Rapamycin (mTOR), controls cell survival, growth, and motility through two distinct multiprotein complexes, mTORC1 (a mammalian counterpart of TORC1) and mTORC2 (a mammalian counterpart of TORC2). Rapamycin (RAPA), an mTOR inhibitor, and its analogs are considered potential candidates for the treatment of GBM. We hypothesize that the contribution of the two complexes are interdependent, resulting in uncontrolled GBM growth and dissemination while providing a molecular basis for therapeutic intervention. The interplay of mTORC1 and mTORC2 was studied in cell lines LN18, U87, and U373. Immunohistochemical analysis demonstrated activated AKT (pAKT) expression in 55% of GBMs. The cells were treated with one of the following, RAPA, LY 294002 (LY), PDGF-BB, or fibronectin (FN), alone or in combination. Levels of phosphorylated AKT, p70S6K, S6K, STAT3, and RhoA, downstream components in the PI3K/PTEN pathway, were assessed by immunoblotting. Treatment with RAPA noticeably reduced activation of AKT at Ser473 by 61% and 72% at 1 and 3 h, respectively, and demonstrated enhanced activation from the baseline thereafter. Pre-treatment with RAPA or LY diminished PDGF-BB or FN stimulation of p70S6K at Thr389. RAPA treatment resulted in sustained suppression of phospho-S6K at Ser 235/236 through a 24h period. A combined treatment with RAPA and LY completely blocked the activation of S6K. Cell survival and growth by PDGF or FN was achieved via the modulation of STAT3; either RAPA or LY alone inhibit this induction, while combined treatment totally abolished PDGF-BB or FN induced phosphorylation of STAT3. Timed treatment with RAPA altered activation of RhoA, a downstream component of the mTORC 2 complex. Cellular motility was determined using radial monolayer cell migration and proliferation was assessed by MTT assay. Cell growth was suppressed 76% and 32% by treatment with LY and RAPA, respectively. Also, pre-treatment with LY plus RAPA reduced PDGF-BB induced cell proliferation. GBM cell migration was reduced by LY treatment but not by RAPA. The results of this study indicate that mTORC1 RAPA-dependent S6K phosphorylation regulates cell proliferation. Activation of mTORC2 is decreased initially but activated by prolonged RAPA treatment, which inhibits downstream S6K that acts as a negative feedback modulator of IRS-1, in turn promoting upstream pAKT signaling. Thus, combining PI3K/AKT and mTORC2 inhibitors in conjunction with RAPA treatment may provide novel targets for GBM therapy.
BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2<sup>+</sup>), locally advanced or metastatic breast cancer (BC).
Authors: Sara A. Hurvitz, Fabrice Andre, Howard A. Burris, Masakazu Toi, Marc E. Buyse, Tarek Sahmoud, Pabak Mukhopadhyay, Cristian Massacesi, Tanya Taran, Jennifer Ko, Matthieu Rupin
Journal: Journal of Clinical Oncology (2012)

TPS648 Background: Up to 25% of BCs overexpress human epidermal growth factor receptor 2 (HER2). Patients with HER2 + disease have a higher rate of relapse and shorter overall survival (OS). Trastuzumab, a monoclonal antibody targeting HER2, is the standard of care and improves OS for HER2 + BC, but acquired resistance is common. The combination of trastuzumab and paclitaxel has shown good tolerability and excellent objective response rates (ORR) in up to 84% of patients with HER2 + metastatic BC (MBC) (Gasparini G, et al. BCRT. 2007;101:355-65). Everolimus is an orally bioavailable inhibitor of mammalian target of rapamycin (mTOR), a protein kinase central to multiple protein synthesis pathways and implicated in trastuzumab resistance. Everolimus-containing regimens have shown promising results in patients with ER + , HER2 – advanced BC in phase II/III trials; everolimus plus trastuzumab/paclitaxel or vinorelbine has shown encouraging ORR with an acceptable safety profile in phase I/II trials in patients with HER2 + MBC. The present phase III study was undertaken to assess the effectiveness of adding everolimus to first-line standard therapy in HER2 + advanced BC. Methods: Women with HER2 + , locally advanced or metastatic BC who have received no prior systemic therapy (except endocrine) are eligible. Local disease must not be amenable to resection with curative intent. Women with a history of central nervous system metastasis are excluded. Patients are randomized 2:1 (everolimus vs control) to receive standard therapy (paclitaxel and trastuzumab) plus everolimus (10 mg daily) or placebo. The primary endpoint is progression-free survival. Secondary endpoints include OS, ORR, and clinical benefit rate. Additional endpoints are safety, performance status, and biomarkers. This trial is sponsored by Novartis Pharmaceuticals and is registered (ClinicalTrials.gov: NCT00876395). Enrollment began September 2009, with a planned accrual of 717. The current accrual is 719, and the estimated primary completion date is October 2012.
qSOFA for Identifying Sepsis Among Patients With Infection
Authors: François Lamontagne, David A. Harrison, Kathryn M. Rowan
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies
Authors: G David Batty, Tom C Russ, Emmanuel Stamatakis, Mika Kivimäki
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To examine the role of psychological distress (anxiety and depression) as a potential predictor of site specific cancer mortality. <b>Design</b>&nbsp;Pooling of individual participant data from 16 prospective cohort studies initiated 1994-2008. <b>Setting</b>&nbsp;Nationally representative samples drawn from the health survey for England (13 studies) and the Scottish health survey (three studies). <b>Participants</b>&nbsp;163 363 men and women aged 16 or older at study induction, who were initially free of a cancer diagnosis, provided self reported psychological distress scores (based on the general health questionnaire, GHQ-12) and consented to health record linkage. <b>Main outcome measure</b>&nbsp;Vital status records used to ascertain death from 16 site specific malignancies; the three Scottish studies also had information on cancer registration (incidence). <b>Results</b>&nbsp;The studies collectively contributed an average of 9.5 years of mortality surveillance during which there were 16 267 deaths (4353 from cancer). After adjustment for age, sex, education, socioeconomic status, body mass index (BMI), and smoking and alcohol intake, and with reverse causality (by left censoring) and missing data (by imputation) taken into account, relative to people in the least distressed group (GHQ-12 score 0-6), death rates in the most distressed group (score 7-12) were consistently raised for cancer of all sites combined (multivariable adjusted hazard ratio 1.32, 95% confidence interval 1.18 to 1.48) and cancers not related to smoking (1.45, 1.23 to 1.71), as well as carcinoma of the colorectum (1.84, 1.21 to 2.78), prostate (2.42, 1.29 to 4.54), pancreas (2.76, 1.47 to 5.19), oesophagus (2.59, 1.34 to 5.00), and for leukaemia (3.86, 1.42 to 10.5). Stepwise associations across the full range of distress scores were observed for colorectal and prostate cancer. <b>Conclusion</b>&nbsp;This study contributes to the growing evidence that psychological distress might have some predictive capacity for selected cancer presentations, in addition to other somatic diseases.
Investigation of the Subcellular Neurotoxicity of Amyloid‐β Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance
Authors: Wei Li, Zhen Xu, Bingzhe Xu, Chung Yuen Chan, Xudong Lin, Ying Wang, Ganchao Chen, Zhigang Wang, Qiuju Yuan, Guangyu Zhu, Hongyan Sun, Wutian Wu, Peng Shi
Journal: Advanced Healthcare Materials (2017)

Alzheimer's disease (AD) is a neurodegenerative disorder with the histopathological hallmark of extracellular accumulation of amyloid‐β (Aβ) peptide in brain senile plaques. Though many studies have shown the neural toxicity from various forms of Aβ peptides, the subcellular mechanisms of Aβ peptide are still not well understood, partially due to the technical challenges of isolating axons or dendrites from the cell body for localized investigation. In this study, the subcellular toxicity and localization of Aβ peptides are investigated by utilizing a microfluidic compartmentalized device, which combines physical restriction and chemotactic guidance to enable the isolation of axons and dendrites for localized pharmacological studies. It is found that Aβ peptides induced neuronal death is mostly resulted from Aβ treatment at cell body or axonal processes, but not at dendritic neurites. Simply applying Aβ to axons alone induces significant hyperactive spiking activity. Dynamic transport of Aβ aggregates is only observed between axon terminal and cell body. In addition to differential cellular uptake, more Aβ‐peptide secretion is detected significantly from axons than from dendritic side. These results clearly demonstrate the existence of a localized mechanism in Aβ‐induced neurotoxicity, and can potentially benefit the development of new therapeutic strategies for AD.
Risk Stratification in Acute Promyelocytic Leukemia Based on Elevated White Cell Count and Reduced Platelet Count Does Not Identify Subsequent Relapses: A Retrospective Review of 60 Patients.
Authors: Richard T. Doocey, Stephen H. Nantel, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Thomas J. Nevill, John D. Shepherd, Kevin W. Song, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith
Journal: Blood (2004)
Randomized Comparison of Cladribine with Cyclophosphamide and Fludarabine with Cyclophosphamide in Previously Untreated Progressive and Symptomatic Chronic Lymphocytic Leukemia: The Interim Analysis of PALG CLL3 Trial.
Authors: Tadeusz Robak, Jerzy Z. Blonski, Joanna Gora-Tybor, Jacek Najda, Beata Stella-Holowiecka, Malgorzata Calbecka, Malgorzata Kowal, Anna Dmoszynska, Bernadeta Ceglarek, Lech Konopka, Tomasz Szpila, Krzysztof Warzocha, Jaroslaw Piszcz, Janusz Kloczko, Krystyna Zawilska, Andrzej Mital, Andrzej Hellmann, Stanislaw Potoczek, Kazimierz Kuliczkowski, Kazimierz Sulek, Andrzej Zdunczyk, Marek Kasznicki
Journal: Blood (2005)
Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial
Authors: Zoltan Szakacs, Yves Dauvilliers, Vladimir Mikhaylov, Irina Poverennova, Sergei Krylov, Slavko Jankovic, Karel Sonka, Philippe Lehert, Isabelle Lecomte, Jeanne-Marie Lecomte, Jean-Charles Schwartz, Mikhail Poluektov, Eduard Yakupov, Alexander Kalinkin, Murat Aksu, Hikmet Yilmaz, Gülcin Benbir, Dorota Wolynczyk-Gmaj, Wojchiech Jernajczyk, Ivan Staykov, Arben N Tavarari
Journal: The Lancet Neurology (2017)
Discovery of Selective Small Molecule Pan-Pim Kinase Inhibitors with Potent Oral Efficacy in Murine Xenograft Models.
Authors: Sean O'Brien, Mustapha Haddach, Cosmin Borsan, Jerome Michaux, Pauline Kerdoncuff, Mike Schwaebe, Fabrice Pierre, Eric Stefan, Anne Sophie Nedellec, Adam Siddiqui-Jain, Nicole Streiner, Diwata Macalino, Denis Drygin, Caroline Ho, Josh Bliesath, May Omori, Ryan Stansfield, Jennifer Phung, David Ryckman, William Rice, Kenna Anderes
Journal: Blood (2009)
Musculoskeletal Low Back Pain in School-aged Children
Authors: James MacDonald, Emily Stuart, Richard Rodenberg
Journal: JAMA Pediatrics (2017)

<h3>Importance</h3> Low back pain (LBP) in children and adolescents is a common problem. The differential diagnosis of LBP in this population is broad and different from that seen in the adult population. Most causes of LBP are musculoskeletal and benign in their clinical course. Clinicians should have an understanding of the relevant anatomy and the most commonly encountered etiologic factors of LBP in children and adolescents to provide effective care. <h3>Observations</h3> Low back pain is rarely seen in youth before they reach school age. Subsequently, rates of LBP rise until age 18 years, at which age the prevalence of LBP is similar to that in adults. The differential diagnosis of LBP in this population is broad, and individual etiologic factors are most often associated with musculoskeletal overuse or trauma. Sinister etiologic factors are rare. The patient's history and physical examination are the foundation of evaluating a child with LBP. The indication for and timing of specific imaging or other studies will vary depending on the etiologic factor of concern. Most treatment of LBP in this population is centered on relative rest, rehabilitation, and identification of predisposing risk factors. Pharmacologic treatment may be used but is typically a brief course. Orthopedic, rheumatologic, and other subspecialty referrals may be considered when indicated, but most of these patients can be managed by a general pediatrician with a good understanding of the principles described in this article. <h3>Conclusions and Relevance</h3> Low back pain in children and adolescents is a common problem. It is most often nonspecific, musculoskeletal, and self-limiting. Pediatricians should recognize the importance of a proper history, physical examination, and general knowledge of the lumbar spine and pelvic anatomy relevant to the child in their evaluation with this presenting symptom.
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Authors: Emelia J. Benjamin, Michael J. Blaha, Stephanie E. Chiuve, Mary Cushman, Sandeep R. Das, Rajat Deo, Sarah D. de Ferranti, James Floyd, Myriam Fornage, Cathleen Gillespie, Carmen R. Isasi, Monik C. Jiménez, Lori Chaffin Jordan, Suzanne E. Judd, Daniel Lackland, Judith H. Lichtman, Lynda Lisabeth, Simin Liu, Chris T. Longenecker, Rachel H. Mackey, Kunihiro Matsushita, Dariush Mozaffarian, Michael E. Mussolino, Khurram Nasir, Robert W. Neumar, Latha Palaniappan, Dilip K. Pandey, Ravi R. Thiagarajan, Mathew J. Reeves, Matthew Ritchey, Carlos J. Rodriguez, Gregory A. Roth, Wayne D. Rosamond, Comilla Sasson, Amytis Towfighi, Connie W. Tsao, Melanie B. Turner, Salim S. Virani, Jenifer H. Voeks, Joshua Z. Willey, John T. Wilkins, Jason HY. Wu, Heather M. Alger, Sally S. Wong, Paul Muntner
Journal: Circulation (2017)